Equities Analysts Offer Predictions for Evotec Q1 Earnings

Evotec AG (NASDAQ:EVO) – Equities research analysts at HC Wainwright lowered their Q1 2027 EPS estimates for Evotec in a report released on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.02. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS and Q4 2027 earnings at $0.04 EPS.

Evotec (NASDAQ:EVO) last announced its earnings results on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The business had revenue of $297.02 million for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%.

EVO has been the topic of several other reports. TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a report on Wednesday. Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

Evotec Stock Down 6.1%

EVO stock opened at $2.01 on Thursday. Evotec has a 12 month low of $1.97 and a 12 month high of $4.41. The company has a quick ratio of 1.60, a current ratio of 1.68 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $2.79 and a 200 day moving average price of $3.03.

Institutional Trading of Evotec

Several institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd grew its stake in Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after purchasing an additional 3,709 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Bank of America Corp DE raised its position in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares in the last quarter. Apollon Wealth Management LLC bought a new stake in Evotec during the 1st quarter valued at $28,000. Finally, Marshall Wace LLP purchased a new stake in shares of Evotec in the 4th quarter worth $40,000. Institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.